Shares of PaxMedica (NASDAQ:PXMD) shot up 110% in early trading after the biotech company said that it now expects to file its New Drug Application for PAX-101 in the second half of 2024. The biotech company said it received constructive feedback at a recent type-B meeting with the FDA that will help it complete the application. It added that most of the work...
5% Dividend Yield, with 100% upside Share Potential The world’s largest provider of hair testing for drugs of abuse announced financial results for the first quarter ended March 31, 2023 And the declaration of a cash dividend of $0.07 per share to be paid on June 8, 2023, to shareholders of record as of May 25, 2023 The Company’s revenue for the quarter ended...
With Current mkt cap of 28MM USD this small cap has been contantly generating cash over the past 6 years. With a patented techfor drug detection its a great target for M&A or LBO. With super good dividend yield, this stock is definetelly gonna fly very soon. Minimum 80% target return. Out of the 28MM the company has 5MM in cash and generates 5-10MM on CFO...
company with a few decades of history, niche product/ market, remains fairly innovative debt vs. cash +cash flow is net positive. low share count float Buyout Target